Risk of hyperprolactinemia and extrapyramidal symptoms in antipsychotic-treated schizophrenia: a retrospective single-center real-world study.

Shao Y, Lu Z, Zhang Y, Wang X

Open source

DOI
10.3389/fphar.2026.1884159
Published
2026
Container
Frontiers in pharmacology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2026.1884159,
  title = {Risk of hyperprolactinemia and extrapyramidal symptoms in antipsychotic-treated schizophrenia: a retrospective single-center real-world study.},
  author = {Shao Y and Lu Z and Zhang Y and Wang X},
  year = {2026},
  journal = {Frontiers in pharmacology},
  doi = {10.3389/fphar.2026.1884159},
  url = {https://doi.org/10.3389/fphar.2026.1884159}
}

RIS

TY  - JOUR
TI  - Risk of hyperprolactinemia and extrapyramidal symptoms in antipsychotic-treated schizophrenia: a retrospective single-center real-world study.
AU  - Shao Y
AU  - Lu Z
AU  - Zhang Y
AU  - Wang X
PY  - 2026
JO  - Frontiers in pharmacology
DO  - 10.3389/fphar.2026.1884159
UR  - https://doi.org/10.3389/fphar.2026.1884159
ER  - 

APA

Y, S., Z, L., Y, Z., & X, W. (2026). Risk of hyperprolactinemia and extrapyramidal symptoms in antipsychotic-treated schizophrenia: a retrospective single-center real-world study.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2026.1884159

Source records